VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog🤝Partner
Illustration for: Seven Blank-Check Deals Hit the Market in Three Days
Value Add VC/Pulse/IPO$10 per unit

Seven Blank-Check Deals Hit the Market in Three Days

Between August 3 and August 5, three SPACs priced at $10 a unit and four more filed or amended registration statements with the SEC -- the densest run of blank-check activity of the summer.

By the Numbers

3
SPACs priced
4+
New/amended filings
$10.00
Standard unit price
Aug 3-5, 2026
Window
TC
Trace Cohen
Early-stage VC & angel · Founder, New York Venture Partners
August 5, 2026
1 min read
ShareXLinkedInEmail
TC

The VC Read · Trace's Take

Trace Cohen

SPACs are back and nobody's writing about it because the 2021 cohort burned everyone. That's exactly why founders should read the terms: smaller trusts, earned promotes, redemption assumed. If you're a $400M-$1.5B growth company with no path to a traditional listing and a crossover round you can't get done, a sponsor will call you in the next six months. The number that decides whether it's real money is the redemption rate at close -- ask for the sponsor's committed backstop and PIPE before anything else.

Analysis

A Denser Run Than Any Other Week This Summer

Blank-check activity clustered heavily in the first three trading days of August. Per [stockanalysis.com's IPO tracker](https://stockanalysis.com/ipos/2026/) and SEC EDGAR filings, the run included:

  • **TCGX Acquisition Corp.** (TCGX) -- priced August 5, 7.5 million units at $10.00
  • **ARC Group Securities Acquisition I** (FJDI) -- priced August 4 at $10.00
  • **BOA Acquisition Corp. II** (THEO) -- priced August 4 at $10.00
  • **GX Acquisition Corp. III** (GXTR) -- filed August 3, 20 million shares at $10.00
  • **1776 Acquisition Corp** (SVSX) -- filed August 3, 15 million shares at $10.00
  • **Gravity Acquisition Corp.** -- new S-1 filed August 5
  • **Luminous Acquisition** -- new S-1 filed August 4

“II** (THEO) -- priced August 4 at $10.00 - **GX Acquisition Corp.”

Four additional vehicles filed S-1/A amendments on August 4 alone: Pinnacle Acquisition Corp, Leader's Advantage Acquisition Corp., Hall Chadwick Acquisition Corp II and Crestone Strategic Capital Acquisition Corp. Amendments are the step immediately before pricing, so the near-term calendar is heavier still.

The structure being sold in 2026 is not the 2021 structure. Trusts are smaller -- $75 million to $200 million rather than $300 million-plus -- sponsor promotes are more often reduced or earned rather than fixed at 20%, and redemption terms are written assuming most public shareholders will redeem. Sponsors are underwriting to a smaller, more certain pool of capital at close.

The reason this matters to private companies is arithmetic, not enthusiasm. Roughly 40 vehicles with two-year deadlines create roughly 40 firms actively hunting targets in the $300 million to $1.5 billion range -- exactly the band where growth-stage companies are stuck between an exhausted crossover market and a traditional IPO calendar dominated by biotech and mega-caps. The 2021 cohort's post-merger returns were poor enough that most institutional investors still will not touch de-SPAC equity, and nothing in this batch has changed that. What to watch is the first 2026-vintage vehicle to announce a technology target, and what redemption rate it clears with.

ShareXLinkedInEmail

Analysis and editorial commentary by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.

Read Next

IPO· Aug 5, 2026

Braveheart Bio Prices $300M IPO for Heart Drug

Illustration for: Braveheart Bio Prices $300M IPO for Heart Drug
IPO$300M IPO

Braveheart Bio Prices $300M IPO for Heart Drug

Braveheart Bio priced 18.75M shares at $16 to raise $300M on Nasdaq, funding its lead drug BHB-1893 for hypertrophic cardiomyopathy in the same week two other biotechs also priced.

IPO· Aug 5, 2026

Vogenx Prices $68M IPO for Metabolic Drug

Illustration for: Vogenx Prices $68M IPO for Metabolic Drug
IPO~$67.8M net

Vogenx Prices $68M IPO for Metabolic Drug

Vogenx priced 6.25M shares at $12 to raise roughly $68M net, funding development of mizagliflozin, an SGLT1 inhibitor for gastrointestinal and metabolic disorders, through 2028.

IPO· Aug 5, 2026

Attovia Prices $289M Nasdaq IPO at $17 a Share

Illustration for: Attovia Prices $289M Nasdaq IPO at $17 a Share
IPO$289M IPO

Attovia Prices $289M Nasdaq IPO at $17 a Share

Attovia Therapeutics priced 17 million shares at $17 to raise $289M on Nasdaq under the ticker ATTO, the largest operating-company listing of the first week of August.

@Trace_Cohen·t@nyvp.com